Month: November 2011

-la PTI is a disease characterized by deficiency of blood platelets, causing hemorrhages in the skin, mucous membranes and other bodies

– estimated a prevalence of 10 adults per 100,000 inhabitants, occurring mostly in women (70%)

-The diagnosis of female carriers and prenatal study, elements highlighted in the approach of the hemofilias

-25% of patients with haemophilia A serious develops inhibitors which block therapeutic clotting factors, and treatment are therefore useless

-the treatment of bleeding in patients with inhibitor and inhibitor elimination are the main problems posed by the approach of the Hemophilia

-Forms moderate and mild von Willebrand disease present a prevalence of 1%

Zaragoza, November 2011- hemorrhagic diseases are all those general processes in which there is a tendency to bleed, to greater or lesser degree, without a clear local cause that justifies. These pathologies are distributed into two groups: those arising from clotting factors and platelet function abnormalities, (where the Hemophilia and von Willebrand disease are the most common hereditary disorders), and the due to a decrease in the number of platelets in blood (thrombocytopenia)generally immune origin. “ Moderate and mild forms of von Willebrand disease present a prevalence of 1% ”, according to Dr. Luis Javier García Frade, head of the service of Hematology of the Hospital Universitario in the Río Hortega, in Valladolid, and Vice-Chairman of the Committee scientist of the LIII meeting national of the Spanish society of Haematology and haemotherapy (AEHH) and the XXVII National Congress of the Spanish society of thrombosis and Haemostasis (SETH).

“ Hemophilia A presents a prevalence of up to 10 people for every 100,000 inhabitants, while haemophilia B is suffering by up to two people per 100,000 inhabitants ”, says the expert. It’s hereditary processes linked to the x-chromosome, in such a way that are transmitted by women, but endured by men, with exceptions. In this context, “ early diagnosis of female carriers and prenatal study are two elements in the approach of these pathologies ”, adds. 25% Of patients with haemophilia A serious develops inhibitors which block therapeutic clotting factors, and treatment are therefore useless. This is the main problem with the current approach of hemophilia. The treatment of bleeding in patients with inhibitor and inhibitor elimination are the main problems posed by the current approach of this disease.

PTI: disease characterized by an abnormally low number of platelets in blood

Idiopathic Thrombocytopenic Purpura (ITP) is a disease characterized by the decrease in blood platelets, causing hemorrhages in the skin, mucous membranes and other bodies. “ Although the causes are unknown, it is known that the immune system produces antibodies against platelets to destroy them ”, says Dr. García Frade. It is estimated a prevalence of 10 adults per 100,000 inhabitants, occurring mostly in women (70%). There is this difference between men and women from age 60. “ The chronicity of the disease occurs in 80% of adults and 20 per cent of children ”, said. The annual in this group of population incidence reaches 8 cases per 100,000 inhabitants.

“ Serious bleeding Fortunately, are rare and usually occur in patients with platelet numbers below 10,000 by microliter of blood ”, according to the expert. Similarly, mortality is less than 1%, so the current goal of treatment is achieve a safe blood platelet number, rather than to cure the disease. “ Haemorrhage and its chronicity aspects affecting negatively the quality of life for these patients are ”, stresses. “ Antibiotic agents of the trombopoyesis (the process by which platelets are generated), emerging, they have proved their effectiveness in randomized trials, and continue making studies of long-term security ”, points out Dr. García Frade.

Dr. Gregory Cheng, of the Chinese University of Hong Kong, has been invited to participate in the national meeting LIII of the AEHH and XXVII National Congress of the SETH, to discuss emerging therapies for adult patients with chronic ITP, among Eltrombopag.

The Department of Hematology of the Dr. Cheng has participated in numerous clinical trials phase I-III for research on innovative therapies, the results have been published in prestigious scientific journals. In this sense, this expert “ better understanding of the pathophysiology of the PTI has determined a change in treatment ”.

In the framework of this Congress were recent clinical data of these new actors, including the adverse effects of special interest in the approach of this pathology. This is the case of the EXTEND study on tolerability and the safety profile of Eltrombopag, “ treatment significantly increases the count of platelets and reduces the incidence of bleeding in these patients ”, says.

On the Spanish society of thrombosis and Haemostasis (SETH)

The Spanish society of thrombosis and Haemostasis (SETH) aims to bring together graduates and doctors in medicine and surgery, pharmacy, chemistry, biology and other sciences related, interested in the research of thrombosis and Haemostasis, as well as your diagnosis, treatment and prophylaxis.

It is, therefore, a society of multidisciplinary nonprofit, to promote research on these issues, as well as the involvement and communication between its members, to make progress in the following facets of the pathology of thrombotic and hemostasis: pathogenesis, prevention, diagnosis and treatment.

To this end, the Society organizes regular sessions, courses, conferences, meetings and few acts considers appropriate to achieve its purpose.